News Article | March 2, 2017
ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Anthony J. Giovinazzo, MBA, to its Board of Directors, effective immediately. “I first met Anthony over twenty years ago, working together on an Alzheimer’s diagnostics opportunity” stated Eugene Williams, ProMIS Executive Chairman. “He and I have been talking about a shared commitment to making a difference in Alzheimer’s for a long time. After the outstanding job that Anthony did at Cynapsus, for both Parkinson’s patients and shareholders, he has many alternatives. We are thrilled that he has chosen to apply his talents and energy to ProMIS”. Anthony Giovinazzo is currently President and CEO of Sunovion CNS Development Canada ULC. As President and CEO of Cynapsus Therapeutics from 2009 through 2016 he led the successful purchase of Cynapsus by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan. At Cynapsus, Anthony led the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies and was responsible for Cynapsus up-listing from the TSX Venture exchange to the TSX and then the NASDAQ. “I am delighted to join the Board of Directors of ProMIS Neurosciences,” stated Mr. Giovinazzo. “Having devoted most of my career to the development and commercialization of therapies for neurodegenerative disease, I look forward to leveraging my experience to support the Company as it develops innovative, precision medicine therapeutics for Alzheimer’s disease and ALS”. About Anthony Giovinazzo, MBA. Anthony J. Giovinazzo has over thirty-eight years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. Over the subsequent eight years Anthony worked in Fortune 100 investment banking and private equity. For the last twenty-three years he worked exclusively on the discovery, development and commercialization of neurodegenerative disease therapeutics. His primary areas of focus have been Alzheimer’s, Parkinson’s and neuropathic pain. Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals Inc., a member of the Dainipon Sumitomo Pharma group of companies of Japan. He was President, CEO and a Director of Cynapsus Therapeutics Inc. from 2009 to 2016 and was one of the three original inventors and patent holders of the Cynapsus Parkinson’s focussed technology. Under his leadership the company successfully developed APL 130277 (a sublingual strip of apomorphine for OFF episodes) through to late stage Phase 3 studies. In addition, Anthony led the up-listing of Cynapsus from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA. The sale of Cynapsus to Sunovion in 2016 resulted in a 120% premium to market price (CDN$841 million) via an all cash M&A transaction. Mr Giovinazzo is the co-author of several peer reviewed papers and author of several papers on strategic and financing issues in the biopharmaceutical industry. He was a finalist in the E&Y Entrepreneur of the Year (2014) for Ontario Canada. He is a Chartered Director and Audit Committee Certified, both from The Directors College, a degree granting affiliate of Mc Master University, Hamilton Canada. He also has completed the Leadership and Strategy in Pharmaceuticals and Biotech, in 2006 from Harvard Business School, Boston, MA; a Masters of Business Administration from IMD, Geneva Switzerland in 1986; Graduate Certificate Studies in Canadian Law Osgoode Hall Law School, York University, Toronto, in 1984; and his Bachelor of Arts in Economics and Accounting at McMaster University in 1978. The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS. ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please consult the Company's website at: http://www.promisneurosciences.com Like us on LinkedIn
News Article | May 10, 2017
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector IMD product candidate for OTC Deficiency, expected 2H 2017 CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today reported financial results for the first quarter ended March 31, 2017, and provided a corporate update. The company announced its decision to discontinue the development of DTX101, an investigational AAVrh10-based gene therapy product in development for the treatment of moderate/severe-to-severe hemophilia B. The decision followed the review of the emerging DTX101 Phase 1/2 clinical study data, including the data as of the beginning of May 2017, and the observation that the data would not meet the company’s minimum target product profile for continued development or future commercialization. Dimension plans to present full study findings, including results from ongoing immune and biomarker analyses, at a future scientific conference. “We are disappointed with the outcome of our DTX101 program, addressing an important disease with significant unmet need; however, our Phase 1/2 open-label clinical study did not demonstrate an ability to achieve a minimum target product profile for continued development or future commercialization,” said Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. “We deeply appreciate the participation by the investigators and staff, patients and caregivers who all contributed to the conduct and execution of this Phase 1/2 clinical trial. Further, Dimension remains committed to the hemophilia community through continued investment in the Company’s ongoing IND-enabling activities for DTX201 for hemophilia A, in collaboration with Bayer, and the follow-up of the six patients dosed with DTX101 in the Phase 1/2 clinical trial through an extension study that will monitor all patients for a total of five years.” Dr. Jenkins continued, “We remain excited about the opportunities around our IMD portfolio, which, unlike DTX101, utilizes the AAV8 capsid, and look forward to initial data later this year with DTX301 for OTC deficiency.” The company does not believe the outcome of the DTX101 program will affect the ongoing Phase 1/2 clinical development of DTX301, Dimension’s lead AAV8-based gene therapy, in OTC deficiency, or current vector design for the company’s other investigational AAV therapeutic programs in development. While the company remains focused on the development of our IMD programs testing AAV8 based vectors, it will be undertaking a comprehensive portfolio prioritization review to thoroughly examine resources and the opportunities to focus efforts, which review is expected to be completed by the end of the second quarter of 2017. • Continued to advance robust portfolio of IMD candidates utilizing the capsid serotype AAV8 - DTX301 for OTC deficiency, DTX401 for GSDIa, DTX501 for PKU, DTX701 for Wilson disease, and DTX601 for citrullinemia type I: • DTX201: Currently in IND-enabling studies in collaboration with Bayer for the treatment of moderate/severe to severe hemophilia A. Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, and a collaboration with Bayer in hemophilia A. Dimension has initiated a phase 1/2 clinical trial with DTX301 for the treatment of OTC deficiency. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential productivity of Dimension’s ongoing collaborations, timing and likelihood of achievement of Dimension’s upcoming development milestones, including timing of disclosure of data, the expected progress of Dimension's portfolio and programs, timing and likelihood of regulatory filings and approvals, and our ability to develop and advance product candidates into, and successfully complete, clinical studies. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Dimension’s product candidates, including its candidate, DTX301, will not achieve development milestones, including patient enrollment, dosing of patients, release of initial data, or regulatory filings; and the risks described under the caption "Risk Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q for the period ended March 31, 2017, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics’ additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law. This selected financial information should be read in conjunction with the unaudited, condensed consolidated financial statements and notes included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.
News Article | February 24, 2017
Jon Fredrik Baksaas Född1954. Civilekonomexamen, NHH Norwegian School of Economics & Business Administration, Norge. Styrelseledamot: Svenska Handelsbanken AB. Innehav i Ericsson: Inget.* Huvudsaklig arbetslivserfarenhet och övrig information: Verkställande direktör och koncernchef för Telenor (2002-2015). Har innehaft tidigare positioner inom Telenorkoncernen sedan 1989, däribland vice verkställande direktör, finanschef och chef för TBK AS. Tidigare befattningar innefattar finanschef för Aker AS, finansdirektör för Stolt Nielsen Seaway AS och controller inom Det Norske Veritas, Norge och Japan. Ledamot i styrelsen för GSMA (2008-2016) och ordförande i styrelsen för GSMA (2014-2016). Jan Carlson Född 1960. Civilingenjörsutbildning, Teknisk fysik och elektroteknik, Linköpings universitet. Styrelseordförande: Autoliv Inc. Styrelseledamot: BorgWarner Inc., Svenskt Näringsliv, Teknikföretagen och Trelleborg AB. Innehav i Ericsson: 7 900 B aktier.* Huvudsaklig arbetslivserfarenhet och övrig information: Verkställande direktör och koncernchef för Autoliv Inc. sedan 2007 och styrelseordförande för Autoliv Inc. sedan 2014. Har innehaft tidigare positioner inom Autolivkoncernen sedan 1999, däribland chef för Autoliv Europe, Vice President Engineering och chef för Autoliv Electronics. Tidigare befattningar innefattar verkställande direktör för Saab Combitech och Swedish Gate Array. Eric A. Elzvik Född 1960. Civilekonomexamen, Handelshögskolan i Stockholm. Styrelseledamot: IMD Foundation, Lausanne, och Swiss Swedish Chamber of Commerce, Zurich, Schweiz. Innehav i Ericsson: 10 000 B-aktier.* Huvudsaklig arbetslivserfarenhet och övrig information: Finanschef och medlem av ABB-koncernens Group Executive Committee (2013-2017). Finanschef för enheten ABB Discrete Automation & Motion (2010-2012) och för enheten Automation Products (2006-2010). Tidigare befattningar inom ABB sedan 1984, däribland chefspositioner inom finans, företagsförvärv och nya investeringar. * Antalet aktier motsvarar aktieinnehavet vid tidpunkten för kallelsen och omfattar innehav av närstående samt innehav av ADS, om några.
News Article | February 15, 2017
The Hotel Chicago-Illinois Medical District (IMD) is demonstrating its commitment to the community by a new alliance with American Cancer Society’s (ACS) Hotel Partners Program, a cooperative effort between ACS and a select few hotels in Chicago to provide overnight accommodations for cancer patients. The agreement calls for Hotel Chicago-IMD, which is two blocks away from RUSH Hospital, to provide lodging at the deep discounted flat rate of $100 per night to pre-qualified cancer patients and their accompanying family members or caregivers who are traveling for treatment in the area. “We built this hotel first and foremost as a convenient home-away-from-home for patients or families of loved ones at RUSH,” said Imran Jivani, general manager of the 8-month-old boutique Hotel Chicago-IMD. “We understand that traveling for treatment places an additional emotional and financial burden during an already challenging time. We hope that through this partnership with ACS, we can help make these difficult situations a little easier.” While people battling cancer receive lifesaving treatment, Hotel Chicago-IMD will give them all the comforts they require to make their stay in the city more manageable – beginning with a friendly and caring staff. Operated by Portfolio Hotels & Resorts, the 116-room independent has carved out a niche in the marketplace with its hospitable approach. “From the front desk to housekeeping, our employees always welcome guests with a warm smile and an eager-to-please attitude,” added Jivani. “Usually this 'heart of a servant' philosophy is all that’s needed to make someone’s day a bit brighter.” The art-centric Hotel Chicago-IMD features a selection of room types to fit every patient’s need, including: single full, bunk double twin, and queen/king deluxe – with ADA accessibility. In-room amenities are plentiful too, with items like pillow top mattresses, personal Keurig, refrigerator, microwave, LCD TV with cable, ample closet space and a sizable work area. The property also boasts complimentary Wi-Fi, complimentary coffee, on-site washing machines, a private parking lot and a 24-hour fitness center for those patients who need to exercise. Hotel Chicago-IMD is one of only four hotels in Chicagoland participating in ACS’s Hotel Partners Program. Patients must contact ACS at 1-800-227-2345 to request a room (not the hotel direct). Once eligibility and availability is confirmed, ACS will place the reservation and provide the patient with a hotel confirmation number.
News Article | February 16, 2017
StayNTouch, an innovator in mobile technology and Property Management Systems (PMS) for hotels, announced the deployment of its Rover PMS™ and Zest™ solutions at Hotel Chicago - Illinois Medical District (IMD), a 116-room independent in Chicago’s West Loop neighborhood. “Our guests are savvy travelers who are already self-empowered through their use of technology, so the StayNTouch platform fits right into their lifestyle,” said Imran I. Jivani, General Manager of Hotel Chicago-IMD. “Guests are served in the way guests want to be served. Like many boutique hotels, we run lean, so the self-check-in is a huge relief for our staff, who can instead focus more on servicing people. And the people who don’t want to have a “service moment” are just as happy as those who do. “StayNTouch has given us a competitive edge,” continued Mr. Jivani. “We’re delivering a technology amenity that until recently was only available to the top 5% of big brand hotels and their loyalty members. We offer this new mobile experience to every guest as a standard part of their stay, which levels the field for us.” StayNTouch offers hotels the opportunity to integrate multiple cloud-solutions on one platform: “We are delighted to be working with the team at Hotel Chicago-Illinois Medical District,” said Jos Schaap, CEO-Founder of StayNTouch, “Like many independent hotels, their success is dependent on their ability to provide a service model that aligns with their guests’ expectations. They have shown that forward-facing property management system technology transforms and improves the hotel experience for both staff and guests.” StayNTouch is a “Software as a Service” hotel property management systems (PMS) company focused on developing solutions that help hotels raise service levels, drive revenues, reduce costs, and ultimately change the way hotels can captivate their guests. Developed with mobility in mind, the pioneering platform enables hotels to create long lasting relationships with their guests by delivering personalized service levels that today’s guests require. StayNTouch operates on tablets and smartphones, empowering hotel employees to go above and beyond in exceeding guest expectations at every touch point. Powering over 65,000 rooms globally, our game-changing solution frees hotels from the constraints of legacy or premise systems, dramatically streamlines operations, increases margins, and revolutionizes how front-line staff connect with guests. StayNTouch is a trusted partner to many of the most forward thinking hotels, resorts, casinos and chains in the industry, including Yotel, Zoku Amsterdam, Valencia Hotels, The Freehand Hotels, Porto Vista San Diego and the Fontainebleau Miami Beach. To learn more watch our video "THE NEW WAY... TO HOTEL!" The renovated historic building that houses Hotel Chicago-IMD is conveniently situated in between RUSH Hospital and West Loop’s red hot Randolph Street dining corridor. Hotel Chicago-IMD provides a stylish European boutique option for hospital visitors, students, or savvy travelers looking to enjoy a night on the town. The art-centric property features a multitude of room types to fit every guest, including a single full, a bunk double twin, and a queen/king deluxe, with amenities like: luxurious pillow top mattress, personal Keurig, refrigerator, microwave, LCD TV with cable, ample closet space and cabinetry, sizable work area, complimentary Wi-Fi, 24-hour fitness center, complimentary coffee, in-room safe, on-site washing machines, and a private parking lot with proximity to a local garage. Hotel Chicago-IMD is managed and operated by Portfolio Hotels & Resorts.
Furneaux B.,Maastricht University |
MIS Quarterly: Management Information Systems | Year: 2011
Limited attention has been directed toward examining post-adoption stages of the information system life cycle. In particular, the final stages of this life cycle have been largely ignored despite the fact that most systems eventually reach the end of their useful life. This oversight is somewhat surprising given that end-of-life decisions can have significant implications for user effectiveness, the value extracted from IS investments, and organizational performance. Given this apparent gap, a multi-method empirical study was undertaken to improve our understanding of organizational level information system discontinuance. Research commenced with the development of a broad theoretical framework consistent with the technology-organization- environment (TOE) paradigm. The resulting framework was then used to guide a series of semi-structured interviews with organizational decision makers in an effort to inductively identify salient influences on the formation of IS discontinuance intentions. A set of research hypotheses were formulated based on the understanding obtained during these interviews and subsequently tested via a random survey of senior IS decision makers at U.S. and Canadian organizations. Data obtained from the survey responses was analyzed using partial least squares (PLS). Results of this analysis suggest that system capability shortcomings, limited availability of system support, and low levels of technical integration were key determinants of increased intentions to replace an existing system. Notably, investments in existing systems did not appear to significantly undermine organizational replacement intentions despite support for this possibility from both theory and our semi-structured interviews.
News Article | March 2, 2017
The Global Center for Digital Business Transformation, an initiative of IMD business school and Cisco, and HR consultancy metaBeratung, have identified four competencies and three behaviours that business leaders need in order to excel in the era of digital disruption. A new report, Redefining Leadership for a Digital Age, presents findings from a global survey of more than 1,000 executives across 20 different sectors. In turbulent times, leaders are caught in a technology-change vortex that is drawing in whole industries and creating disruption on an unprecedented scale. An eye-watering 92% of leaders said they are feeling the effects of digital disruption, with one-third rating the impact of digital disruption on their companies as "very significant." Despite the quickening pace of digital innovation, less than 15% of leaders said that they were "very prepared" to meet the demands of a digitally-disrupted business environment. The majority of participants (almost 80%) indicated that they were "starting preparations" or were "fairly prepared" to tackle digital disruption. In light of the clear understanding of the importance of digitisation, the report outlines the following "HAVE" competencies as the most important success criteria for leaders facing a landscape characterized by digital disruption: These digitally-engaged executives are called "Agile Leaders" - those who have adapted and evolved their practise for an environment continuously disrupted by digital technologies and business models. Nearly half (42%) of those identified as Agile Leaders said that they were making more informed business decisions as the result of well-directed data gathering, effective analysis, and good judgment. The report identified the following additional practices that Agile Leaders adopt in a digitally-disrupted business environment: The findings build upon previous research by the Global Center for Digital Business Transformation, which has demonstrated the importance of Digital Business Agility - a set of meta-capabilities that describe an organisation's readiness to sail in the choppy waters of rapid technology and business model change. The survey was supported by in-depth interviews with leaders from both incumbent organisations and disruptive start-ups. Read the full report. Carlos Torres Vila, CEO, BBVA, said: "We are taking decisive steps in the Group's transformation in order to create the best possible experience for current and future customers. The goal is for BBVA to be the best bank of the digital age." Jeff Immelt, CEO, General Electric, said: "What we've tried to do is narrow our focus as a company, to be only those things that have significant core competency. So, that's led us into being a global infrastructure leader... We're playing to the company's strengths, and, at the same time, we're playing to those things that the world needs... That's led us to be more global. It's led us to be more technical. It's led us to exit media, shrink financial services, and be in those things that we think are core to the company." About the Global Center for Digital Business Transformation A joint initiative of IMD and Cisco, the Global Center for Digital Business Transformation (DBT Center), is a global hub for leading research and analysis on digital disruption. www.imd.org/dbtcenter IMD is a top-ranked business school recognized as the expert in developing global leaders through high-impact executive education. The school is 100% focused on real-world executive development, offers Swiss excellence with a global perspective, and has a flexible, customized and effective approach. IMD is based in Lausanne, Switzerland and has an Executive Learning Centre in Singapore. www.imd.org About metaBeratun metaBeratung is a leading Management and HR-Consultancy with offices in Germany, Austria and Switzerland.
News Article | March 2, 2017
LAUSANNE, Switzerland, March 2, 2017 /PRNewswire/ -- The Global Center for Digital Business Transformation, an initiative of IMD business school and Cisco, and HR consultancy metaBeratung, have identified four competencies and three behaviours that business leaders need in order to...
News Article | February 15, 2017
With a new U.S. President in office, businesses across industries are strategizing on how to succeed and prosper under the helm of this new administration - but many are finding themselves ill-prepared for the impending changes. Today, ExecOnline, a provider of elite online executive educational content, released ExecOnline’s Trump Leadership Survey, which evaluates current business leader sentiment around the incoming administration, assesses opportunities and challenges, as well as accounts for how prepared these organizations are to execute against newly defined strategic initiatives. Corporate leaders believe they must make changes as a result of the new administration in order to position their organizations for success. Nearly 8 in 10 business leaders anticipate changing a major strategic decision based on the election. The top ranking changes being 39% of business leaders anticipate changing financial projections, 30% organizational strategy and 30% capital investments. Are these businesses prepared to execute on these changes? According to ExecOnline’s survey, 83% of leaders say that they frequently observe employees resisting change and only 46% of leaders agree that peer leaders effectively create buy-in for change. In fact, business leaders will need to focus on a whole new set of leadership activities and skill sets to manage change in this environment. “For businesses to excel in this new era of U.S. capitalism they must account for more than just scenario planning and set their sights on grooming and nurturing existing and incoming talent,” said Stephen Bailey, Founder and CEO of ExecOnline. “Employees and key stakeholders will be crucial to any businesses success moving forward, as our survey found that the risk of employee division and conflict scored as a much bigger concern for top business leaders than geo-political conflict.” ExecOnline’s Trump Leadership Survey is compiled from two surveys that capture responses from over 1300 respondents from 54 large, U.S.-headquartered companies across 17 industries. ExecOnline enables enterprises to rapidly deliver leadership development to create lasting organizational impact. ExecOnline partners with elite business schools including Berkeley, Columbia, IMD, MIT, and Yale to create university-certified leadership development programs delivered through its proprietary, cloud-based platform. ExecOnline supports more than 130 enterprise customers with more than 6,000 executive graduates having completed its programs.
News Article | March 1, 2017
CHICAGO, March 1, 2017 /PRNewswire/ -- Integrated Modular Design (IMD), a new company specializing in the design and implementation of pre-fabricated healthcare products like bathroom PODs, exam rooms and patient room headwalls, seeks to lead the construction industry toward more...